Ginkgolide B alleviates Parkinson's disease in rats by resisting oxidative stress and inflammatory response and activating PI3K/Akt signaling pathway

Abstract

This study explored the alleviative effect of ginkgolide B on Parkinson's disease (PD) in rats. PD model was established in 20 rats, which were then randomly divided into model and treatment group, 10 rats in each group. Other 10 rats were selected as control group. The treatment group was treated with
ginkgolide B for four weeks. After treatment, compared with model group, in treatment group the behavior test and learning and memory test indexes were improved, the substantia nigra superoxide dismutase and glutathione peroxidase levels were increased, the substantia nigra malondialdehyde and
inflammatory factor levels were decreased, and the substantia nigra phosphorylated phosphatidylinositol3 kinase (p-PI3K)/phosphatidylinositol-3 kinase (PI3K) and phosphorylated serine-threonine protein kinase (p-Akt)/serine-threonine protein kinase (Akt) ratios were increased (all p<0.05). Ginkgolide B can
alleviate PD in rats. The action mechanisms may be related to its resisting oxidative stress and inflammatory response and activating PI3K/Akt signaling pathway.